Exclusive Summary

• Topical NSAIDs are highly recommended as a first-line therapy for osteoarthritis by global guidelines (ACR/OARSI), offering high efficacy without the gastrointestinal risks of oral drugs.
• The hydrogel cataplasm presents an advanced formulation with high skin moisture, superior transdermal absorption, and extremely low sensitization, acting as a premium upgrade over traditional plasters.
• Driven by a rapidly aging global population, there are over 500 million osteoarthritis sufferers worldwide, creating surging demand for safe, highly compliant topical analgesics in emerging markets.
• With originator patents fully expired, China's proven manufacturing capabilities in this high-barrier dosage form deliver originator-equivalent quality combined with aggressive cost advantages to maximize distributor profitability.